Biyobenzer Kavramı ve Türkiye'de Biyobenzerler

ISSN: 1300-0853
Yayın Aralığı: Yılda 6 Sayı
Başlangıç: 1992
Yayıncı: TÜRK TABİPLERİ BİRLİĞİ

Bu yazı ülkemizde pazara girmiş ancak sağlık çalışanları tarafından kavramsal olarak fazla bilinmeyen biyobenzerler konusunda tüm sağlık çalışanlarını bilgilendirme amacıyla kaleme alınmıştır.biyobenzerler konusu ve ilgili kavramlar geniş bir perspektif içinde teknik açıdan tartışılmıştır.

Biyobenzer Kavramı ve Türkiye de Biyobenzerler The Concept of Biosimilar and the Biosimilars in Turkey

This article was written in order to inform all healthcare workers on the biosimilars which entered the market in our country but are conceptually unfamiliar to healthcare workers. The topic of biosimilars and related concepts were discussed from technical aspect in a broad perspective. Key words: Biosimilars, Medicine, Healthcare

PDF

___

Kaynaklar 1. Tsiftsoglou AS, Ruiz S, Schneider CK. Development and regulation of biosimilars: current status and future challenges. BioDrugs. 2013 Jun;27 (3):203-11 2. Schellekens H. Immunogenicity of therapeutic proteins. Nephrol Dial Transplant. 2003;18:1257-9 3. Thorpe R, Wadhwa M. Intended use of reference products & WHO International Standards/Reference Reagents in the development of similar biological products (biosimilars). Biologicals. 2011Sep;39(5):262-5 4. European Medicine Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on non-clinical and clinical development of similar biological medicinal products. 5. Knezevic I, Griffiths E. Biosimilars--global issues, national solutions. Biologicals. 2011Sep;39(5):252-5. 6. İskit AB. Biyobenzerler. OnkoBülten. 2014 Ağustos:6-9 7. Iskit A. Products situation of the biosimiliars in Turkey and in the world. 5th International Eurasian Hematology Congress, Antalya, Turkey, 15-19 October. Leukemia Research 38 (Supp 1) 2014:SP-017.